SRTOY:OTC-Sartorius Stedim Biotech S.A (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 23.6452

Change

+0.72 (+3.12)%

Market Cap

USD 28.34B

Volume

289.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-29 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ESLOF EssilorLuxottica Société ano..

+3.04 (+1.36%)

USD 103.48B
ESLOY Essilor International SA

-1.25 (-1.10%)

USD 102.35B
HOCPY Hoya Corp

-3.07 (-2.44%)

USD 44.03B
HOCPF HOYA Corporation

+2.22 (+1.79%)

USD 43.50B
RSMDF Resmed Inc DRC

N/A

USD 31.41B
CLPBY Coloplast A

-0.17 (-1.36%)

USD 27.63B
CLPBF Coloplast A/S

-6.21 (-4.84%)

USD 27.31B
TRUMF Terumo Corporation

+1.19 (+6.95%)

USD 25.91B
TRUMY Terumo Corp ADR

+0.16 (+0.91%)

USD 25.10B
SDMHF Sartorius Stedim Biotech S.A

N/A

USD 21.72B

ETFs Containing SRTOY

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -13.80% 36% F 31% F
Dividend Return 0.27% 18% F 6% D-
Total Return -13.53% 35% F 30% F
Trailing 12 Months  
Capital Gain -12.62% 62% D 50% F
Dividend Return 0.27% 13% F 4% F
Total Return -12.34% 55% F 48% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -15.10% 9% A- 17% F
Dividend Return -14.90% 9% A- 17% F
Total Return 0.19% 14% F 7% C-
Risk Return Profile  
Volatility (Standard Deviation) 15.94% 97% N/A 92% A
Risk Adjusted Return -93.52% 3% F 6% D-
Market Capitalization 28.34B 93% A 96% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.